Read more here:
VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Registration Enabling Study of VB-111...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh